Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New insulin cocktails aim to speed up meal coverage for type 1 diabetes

NCT ID NCT07090824

Knowledge-focused Sponsor: Stanford University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This early study tests whether two modified insulins (diluted U-200 Humalog and diluted U-500 Humulin) work faster than a current rapid insulin (Lyumjev) in 20 adults with type 1 diabetes who use insulin pumps. Participants receive each insulin after a meal, and researchers measure how quickly and how long the insulin stays in the blood. The goal is to find insulins that act faster to better cover meals without needing to dose beforehand.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
modified insulin formulations (diluted U-200 Humalog and diluted U-500 Humulin)
What this could lead to
If successful, this could point toward faster-acting insulins that improve blood sugar control after meals for people with type 1 diabetes using insulin pumps.
What could go wrong
This is a very small, early-phase study with only 20 people. It measures insulin levels in the blood, not actual blood sugar outcomes, so it may not lead to a practical treatment change.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

10 people

The number who actually took part.

Started

Oct 2025

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: To be eligible for the study, a subject must meet all of the following criteria: 1. 18-60 years of age 2. Clinical diagnosis of type 1 diabetes 3. On insulin pump therapy and continuous glucose monitor for at least 3 months 4. For females of childbearing potential, a negative pregnancy test and not attempting to conceive. 5. Understanding and willingness to follow the protocol and sign informed consent 6. Ability to speak, read and write English Exclusion Criteria: The presence of any of the following is an exclusion for the study: 1. Diabetic ketoacidosis within 3 months 2. Severe hypoglycemia resulting in seizure or loss of consciousness within 3 months prior to enrollment 3. Have donated blood within 8 weeks 4. Have a known clinically significant history of anemia 5. Pregnant or lactating 6. Active infection 7. Any medical condition that, in the investigator's opinion, might interfere with study completion or participant safety. 8. Known seizure disorder 9. Inpatient psychiatric treatment within 6 months 10. Medication instability within 1 month prior to enrollment, including antihypertensive, thyroid, antidepressant, or lipid-lowering medications 11. Suspected drug or alcohol abuse 12. Chronic kidney disease (GFR \< 60 mL/min/1.73m²)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus, type 1 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Insulin Resistance type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus, type 1 Type 1 diabetes mellitus

Contacts and locations

Locations

  • Stanford University

    Palo Alto, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.